ETS1 and acute lymphoblastic leukemia: Despite these limitations, given the safety of ubiquitous Ets1 deletion in mice (21), and since SWI/SNF inhibitors are entering clinical trials (101), our study suggests that ETS1 and cBAF degradation are reasonable therapeutic strategies to test in human T-ALL.